Michael Tillmann

Active Investor

Chairman & Founder

Singapore, Singapore

Michael Tillmann, Chairman & Founder is an active investor based in Singapore, Singapore. This profile covers what Michael Tillmann backs, at which stage, and how founders can reach out in 2026.

Mr. Michael Tillmann serves as Chairman at BluMaiden Biosciences. He Founded Vela Diagnostics and served as its Chief Executive Officer. He is a Co-Founder & serves as Chairman of Kyberlife. He serves as a Chairman at Optellum. He serves as a Board Member at X Zell. He has 25 years of experience in senior executive positions for multinational companies in the pharmaceutical and diagnostics industry. He founded Vela Diagnostics with the vision of establishing the company as a global provider of integrated IVD solutions that address individual customer needs in molecular diagnostics. Previously he was President & CEO for Roche Diagnostics in North America and before that in Asia Pacific and Europe. Before the Roche assignments, He was Managing Director of the start-up company Artus GmbH, which was later acquired by Qiagen. He started his career in a pharmaceutical trading house, Holstein GmbH, as Managing Director, representing over 20 principals in Japan and South East Asia.

Investor type: Angel
Stages: Early Stage Venture
Invests in: Healthcare & BiotechBiotech & PharmaIoT & Connected Devices
Location: Singapore, Singapore
Typical check: $500K
Past investments: 4

Notable investments

Roche Diagnostic Asia PacificBluMaiden BiosciencesRoche Diagnostic Inc.artus GmbH (acquired by Qiagen)

How to reach Michael Tillmann

Angels and operators like Michael Tillmann reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.

Frequently Asked Questions

What does Michael Tillmann invest in?

Michael Tillmann invests in Healthcare & Biotech, Biotech & Pharma and IoT & Connected Devices, typically at Early Stage Venture. Match your sector and stage, then reach out with a personalized pitch.